Contributions
Type: Publication Only
Background
Multiple myeloma (MM) is a neoplastic disorder characterized by clonal proliferation of plasma cells in the bone marrow. Many circulating biomarkers posses variable roles in the pathogenesis of bone disease causing bone distruction. Mast cells (MCs) can produce, store and release many kinds of chemical mediators with angiogenic properties. MCs accumulation has been associated with enhanced tumor growth.
Aims
The purpose of the study is to estimate the participation of RANK-ligand, matrix metalloproteinase 9 (MMP-9), N-terminal telopeptide (Ntx), carboxyterminal propeptide of type 1 collagen (PICP) and mast cell density(MCD) in the process of bone disease in MM patients.
Methods
We studied fifty-two newly diagnosed MM patients, 28 males, 24 females, mean age 64 years. The types of monoclonal proteins were 27 IgG, 18 IgA, 7 light chain, according to ISS:15were in stage I, 18 in stage II, 19 in stage III. Twenty age- and sex-matched healthy subjects were used as control group. We measured serum levels of sRANKL, MMP-9 and Ntx in urine samples by a solid-phase sandwich ELISA, and MCD in bone marrow biopsy samples by immunostaining. Radiographic examination including skull, pelvis, long bones and cervical, thoracic, and lumbar spine was carried out in all patients as a routine staging procedure.
Results
MCD, RANKL and Ntx were significant higher in untreated myeloma patients in comparison to healthy controls (p<0,001 for all cases). All values were increasing in parallel with ISS stage (p<0,001 for MCD, RANKL, MMP-9 and Ntx). There are significant correlations between MCD and MMP-9, RANKL and Ntx (p<0,001 for all cases). No correlation between MCD and PICP was found.
Summary
In conclusion, our results underline that MCD is an important factor responsible for the enhancement of bone involvement in MM. The positive correlation between MCD and circulatin biomarkers of bone disease support the involvement of mast cells in the biology of myeloma cell growth. Moreover MCD could be used as a marker of disease activity.
Keyword(s): Bone disease, Mast cell, Metalloprotease, Multiple myeloma
Type: Publication Only
Background
Multiple myeloma (MM) is a neoplastic disorder characterized by clonal proliferation of plasma cells in the bone marrow. Many circulating biomarkers posses variable roles in the pathogenesis of bone disease causing bone distruction. Mast cells (MCs) can produce, store and release many kinds of chemical mediators with angiogenic properties. MCs accumulation has been associated with enhanced tumor growth.
Aims
The purpose of the study is to estimate the participation of RANK-ligand, matrix metalloproteinase 9 (MMP-9), N-terminal telopeptide (Ntx), carboxyterminal propeptide of type 1 collagen (PICP) and mast cell density(MCD) in the process of bone disease in MM patients.
Methods
We studied fifty-two newly diagnosed MM patients, 28 males, 24 females, mean age 64 years. The types of monoclonal proteins were 27 IgG, 18 IgA, 7 light chain, according to ISS:15were in stage I, 18 in stage II, 19 in stage III. Twenty age- and sex-matched healthy subjects were used as control group. We measured serum levels of sRANKL, MMP-9 and Ntx in urine samples by a solid-phase sandwich ELISA, and MCD in bone marrow biopsy samples by immunostaining. Radiographic examination including skull, pelvis, long bones and cervical, thoracic, and lumbar spine was carried out in all patients as a routine staging procedure.
Results
MCD, RANKL and Ntx were significant higher in untreated myeloma patients in comparison to healthy controls (p<0,001 for all cases). All values were increasing in parallel with ISS stage (p<0,001 for MCD, RANKL, MMP-9 and Ntx). There are significant correlations between MCD and MMP-9, RANKL and Ntx (p<0,001 for all cases). No correlation between MCD and PICP was found.
Summary
In conclusion, our results underline that MCD is an important factor responsible for the enhancement of bone involvement in MM. The positive correlation between MCD and circulatin biomarkers of bone disease support the involvement of mast cells in the biology of myeloma cell growth. Moreover MCD could be used as a marker of disease activity.
Keyword(s): Bone disease, Mast cell, Metalloprotease, Multiple myeloma